Welcome to our dedicated page for Relmada Therapeutics news (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics stock.
Relmada Therapeutics Inc (RLMD) is a clinical-stage biotechnology company pioneering novel treatments for central nervous system disorders. This news hub provides investors and researchers with essential updates on the company's progress in developing NMDA receptor antagonists and innovative CNS therapies.
Access timely announcements about clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection features official press releases and verified news coverage related to RLMD's work in major depressive disorder treatment, chronic pain management, and metabolic disease research.
Key updates include progress reports on late-stage clinical programs, analyses of therapeutic candidates, and corporate developments impacting RLMD's research pipeline. Bookmark this page for direct access to primary source materials and expert commentary on the company's scientific advancements.
Relmada Therapeutics announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, set for June 12, 2024. CEO Sergio Traversa will engage in a fireside chat at 11:20am ET. The company will also conduct one-on-one investor meetings. The event will be webcast live and accessible through the Relmada website, with a replay available for 90 days. This highlights Relmada's strategic engagement with investors and stakeholders in the CNS disease treatment sector.
Relmada Therapeutics, a late-stage biotechnology company focusing on CNS diseases, announced its participation in the 2024 Jefferies Global Healthcare Conference. The event will feature a fireside chat with CEO Sergio Traversa and CFO Maged Shenouda on June 6, 2024, at 7:30am ET in New York, NY. The management team will also host one-on-one investor meetings during the conference. The fireside chat will be webcast live and accessible through the Investors section of Relmada's website, with an archived replay available for 30 days post-event.
Relmada Therapeutics, Inc. provided a corporate update and reported first-quarter 2024 financial results, highlighting advancements in their Phase 3 programs for major depressive disorder treatment. They plan to commence a Phase 1 trial for modified-release psilocybin in obese patients. Financially, research and development expenses decreased, general and administrative expenses lowered, and net cash used in operating activities declined. The net loss was reduced, with the company holding approximately $83.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024.
Relmada Therapeutics, Inc. (RLMD) will release its first quarter financial results on May 8, 2024, followed by a conference call and webcast discussing the results and corporate updates.
FAQ
What is the current stock price of Relmada Therapeutics (RLMD)?
What is the market cap of Relmada Therapeutics (RLMD)?
